OpenBiome

TATAA Announces Formation of Scientific Advisory Board

Retrieved on: 
Tuesday, October 31, 2023
Drug development, OpenBiome, PPD, MIT, AstraZeneca, MPH, McMaster University, MD, Medicinal chemistry, Doctor of Philosophy, Research, ChromeOS, Internal medicine, Growth, Pharmacy, Novartis, Innate immune system, Medicine, Bristol Myers Squibb, Amgen, Drug discovery, Molecular biology, Biomarker, Nobel Prize, United States Air Force Scientific Advisory Board, SAB, Harvard University, Medical device, Pharmaceutical industry, Physiology, Fluid dynamics, Gastroenterology, Ultragenyx, TATAA, Western University, Bioanalysis

GOTHENBURG, Sweden, Oct. 31, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the formation of its Scientific Advisory Board ("SAB").

Key Points: 
  • GOTHENBURG, Sweden, Oct. 31, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the formation of its Scientific Advisory Board ("SAB").
  • "We are excited to have such a distinguished group of experts on our Scientific Advisory Board.
  • The Scientific Advisory Board demonstrates our commitment to delivering innovative solutions and exceptional services to our clients, and we look forward to working closely with them to achieve our goals."
  • said Dr. Sofia Adolfsson, Scientific Officer and Head of Bioinformatics at TATAA.

TATAA Announces Formation of Scientific Advisory Board

Retrieved on: 
Tuesday, October 31, 2023
Drug development, OpenBiome, PPD, MIT, AstraZeneca, MPH, McMaster University, MD, Medicinal chemistry, Doctor of Philosophy, Research, ChromeOS, Internal medicine, Growth, Pharmacy, Novartis, Innate immune system, Medicine, Bristol Myers Squibb, Amgen, Drug discovery, Molecular biology, Biomarker, Nobel Prize, United States Air Force Scientific Advisory Board, SAB, Harvard University, Medical device, Pharmaceutical industry, Physiology, Fluid dynamics, Gastroenterology, Ultragenyx, TATAA, Western University, Bioanalysis

GOTHENBURG, Sweden, Oct. 31, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the formation of its Scientific Advisory Board ("SAB").

Key Points: 
  • GOTHENBURG, Sweden, Oct. 31, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the formation of its Scientific Advisory Board ("SAB").
  • "We are excited to have such a distinguished group of experts on our Scientific Advisory Board.
  • The Scientific Advisory Board demonstrates our commitment to delivering innovative solutions and exceptional services to our clients, and we look forward to working closely with them to achieve our goals."
  • said Dr. Sofia Adolfsson, Scientific Officer and Head of Bioinformatics at TATAA.

Finch Therapeutics Provides an Update on its Phase 3 Trial of CP101 in Recurrent C. difficile Infection

Retrieved on: 
Tuesday, March 1, 2022
Risk, Private Securities Litigation Reform Act, File, Failure, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Patient, OpenBiome, Food, Breakthrough therapy, Security (finance), Safety, FNCH, Microbiota, U.S. Securities and Exchange Commission, FDA, CDI, Letter, SEC, COVID-19, Regulation, Communication, Patent, Marketing, Clostridioides difficile infection, IND, Review, Severe acute respiratory syndrome coronavirus 2, GLOBE, Pharmaceutical industry, Finch

Notwithstanding the partial clinical hold notices, Finch was able to continue dosing patients in its then-ongoing PRISM-EXT Phase 2 open-label trial of CP101 in recurrent CDI as all of the CP101 lots used for PRISM-EXT were manufactured from material donated prior to December 1, 2019.

Key Points: 
  • Notwithstanding the partial clinical hold notices, Finch was able to continue dosing patients in its then-ongoing PRISM-EXT Phase 2 open-label trial of CP101 in recurrent CDI as all of the CP101 lots used for PRISM-EXT were manufactured from material donated prior to December 1, 2019.
  • In January 2021, Finchs then-contract manufacturer, OpenBiome, was released from clinical hold after implementing a direct testing method for SARS-CoV-2 provided by a third-party vendor.
  • Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.

New SARS-CoV-2 Assay by CosmosID Eases Disruptions in Supply Chain for Patient Fecal Microbiota Transplantation

Retrieved on: 
Tuesday, October 5, 2021
Food, Review, FMT, History of the University of Maryland, College Park, DNA, FDA, Johns Hopkins Bloomberg School of Public Health, Human microbiome, Patient, Physician, OpenBiome, US Foods, Public health, CEO, Genomics, University, Iran National Science Foundation, Agriculture, National Science Foundation, Risk, Johns Hopkins University, COVID-19, Food safety, Algorithm, Severe acute respiratory syndrome coronavirus 2, Safety, Clostridioides difficile infection, Medical device, Pharmaceutical industry

OpenBiome will now test its large inventory of FMT treatments manufactured after December, 2019, which had largely been previously ineligible for distribution per the FDA safety alerts.

Key Points: 
  • OpenBiome will now test its large inventory of FMT treatments manufactured after December, 2019, which had largely been previously ineligible for distribution per the FDA safety alerts.
  • The test allows OpenBiome to restore its supply chain of FMT treatments and once again make them widely available to patients.
  • "Screening our inventory using the stool-based assay developed by CosmosID will allow thousands of patients to get much-needed treatment for C. difficile infection.
  • The CosmosID platform uses proprietary sequence analysis algorithms to accurately profile all microorganisms in a metagenomic sample employing next-generation DNA sequencing.